Thursday, June 10, 2010

GameStop and Pier 1: A Tale of Two Retailers

Admittedly, leading video game retailer GameStop (NYSE:GME) and once-struggling furniture and "dustables" retailer Pier 1 (NYSE:PIR) would seem to have little in common. After all, apart from men who are transitioning from bachelorhood to married life, you would not think they share many customers. While that all may be true, I mention them together for a different reason - namely, the businesses are heading in opposite directions and have very different futures.

GameStop - Here Today, Where Tomorrow?GameStop has certainly enjoyed a fine trajectory. On the way towards becoming the leading independent seller of games (with upwards of 20% market share), the company has boasted a 10-year revenue growth rate in excess of 30% and produces very solid returns on capital. Moreover, the company has a nifty little sub-business within its operations trading used games; while used games represent about one-quarter of the company's sales, they produce about half of the gross profit.



For the complete column, please click on the link below: 
http://stocks.investopedia.com/stock-analysis/2010/GameStop-And-Pier-1-A-Tale-Of-Two-Retailers-GME-PIR-BBY-WMT-AMZN-WSM-COST0610.aspx

Satellite Phones Head Into Orbit

Considering all the attention given to iPhones, Blackberries, 4G and other mobile phone topics, investors could be forgiven if they have forgotten that satellite phone systems still existed. Judging by the announcement last week that Iridium Communications (Nasdaq:IRDM) had awarded a major contract to build a new satellite network, the business not only still exists, but has money-making potential ahead of it. 

The New Deal 
On June 2, the satellite phone operator announced that it had awarded a contract for its Iridium NEXT project to a consortium led by France's Thales. The deal, which could be worth in excess of $3 billion, calls for the construction and launch of 72 low-orbit satellites starting in 2015. 


For the complete piece, please go on to:
http://stocks.investopedia.com/stock-analysis/2010/Satellite-Phones-Head-Into-Orbit-IRDM-BA-LMT-BLL-FSL-MOT-ORB0610.aspx

Sequencing Wars - The Third Generation

Forget the white lab coats and the quiet demeanors. In biology labs across the country, and in corporate R&D labs, there is an all-out war going on. Researchers are pushing themselves and their gear in an effort to understand human disease and find new pathways for treatment, while companies are pushing each other on a relentless drive to build better, faster, and cheaper research equipment. (Learn more about the importance of Research and Development, see: Buying Into Corporate Research & Development (R&D).)

We are now on the cusp of a new battle - the sequencing wars to be fought with third-generation sequencing equipment. Third-gen systems promise more accuracy, faster results, better economics, and a new round of sales for major corporations. The combatants will include some of the better-known names in life sciences research, while the victors will almost certainly include all of us, as these technology innovations should ultimately lead directly to better healthcare treatments.   



For the full column, please continue on to: 
http://stocks.investopedia.com/stock-analysis/2010/Sequencing-Wars---The-Third-Generation-ILMN-LIFE-A-CALP-GE0610.aspx

I also would like add that IBM is working on a next-gen platform as well. IBM's idea is to use microtubules that read the charge of the base-pairs in the DNA. IBM thinks they may be able to produce entire genomes in under an hour with this technology. It's very interesting technology, but it's a long way from "interesting in the lab" to break-out commercial success.
 

Green China

Whenever you read about environmental topics in China, the news is almost always bad. Whether it is problems with air quality in Beijing or water quality in the provinces, there is no shortage of bleak reports about the degradation of nature within China's borders. 

This may not be the full picture, though. True, China has a lot of polluting industries and generates a considerable amount of electricity from older coal-burning plants. The country also has the challenge of figuring out how to provide power, heat, and transportation to a huge population with increasing needs. But China also has considerable financial resources and a political structure that can more easily mandate and advance specific technologies.

With that in mind, it may not be too long before a green China is possible.


For the complete article, please go to: 
http://stocks.investopedia.com/stock-analysis/2010/Green-China-STP-YGE-JASO-GE-CCJ-BTU-ABB0610.aspx

Wednesday, June 9, 2010

Is The Government Pushing Its Luck With BP?

Another day, another volley from the federal government lobbed at BP (NYSE: BP). This time, though, the survival of the company may now actually be in question.

Today's news has the Interior Secretary "encouraging" BP to pay the salaries of oil workers laid off because of the government's decision to impose a six-month moratorium on offshore drilling and completion activities. I have no idea how much money this will ultimately be, nor how many people the government will try to shove under BP's umbrella, but it feels safe to assume that it will be quite a bit of money.

Am I the only one here who thinks this smacks of what you hear about in the third world, where governments charge the families of political prisoners for the costs of their incarcerations and/or executions?

In any case, this comes on top of the already $1.3B+ in likely economic damages that BP will have to pay, to say nothing of billions more that the U.S. government is going to attempt to levy in civil and criminal penalties. On top of *that*, figure on even more lawsuits (class action and otherwise) to come from people who incurred real damages from this spill and those who simply see a chance to chase a fat, juicy ambulance.

Right now speculation is starting to swirl about whether or not BP will have to seek bankruptcy protection. As of the end of 2009, BP had about $101B in positive book value, about $37 billion in debt, and about $8 billion in cold hard cash.

I think bankruptcy is probably a stretch at this point. That $8 billion in cash does not include any ongoing positive free cash flow (which could easily be $7 billion or more per year), so unless the government drastically overplays its hand, I just don't see the company coming to such dire financial straits that bankruptcy is financially necessary. Remember, it will take up to a decade for all of this to get resolved and BP won't be writing big checks for some time to come.

What could happen, though, is a strategic bankruptcy for the U.S. subsidiary of BP. I truly have no idea how that would impact the legal wranglings that are going to involve BP for a decade to come. I would suspect that a bankruptcy of the U.S. subsidiary would be a large middle finger extended towards Washington, D.C. and would complicate efforts to get payments from BP above and beyond any assets residing in the U.S. subsidiary. On top of all that, I have to wonder if this is going to become a diplomatic issue at some point; I cannot imagine that the U.S. government would let a foreign government push ExxonMobil (NYSE: XOM) or Chevron (NYSE: CVX) to the point of bankruptcy, so I have to think that the British government gets involved before too long.

Along similar lines, the ongoing trouble for BP looks increasing bad for Anadarko (NYSE: APC) (BP's partner), Halliburton (NYSE: HAL), and Transocean (NYSE: RIG). The worse this situation gets, the more incentive BP has to spread the economic damage. Though I still think Transocean (and Cameron (NYSE: CAM) walk away from this in good shape, Halliburton and Anadarko could have something to worry about.

On top of that, the knock-on effects to offshore players like Apache (NYSE: APA), Cal-Dive (NYSE: DVR) shouldn't be ignored, as the cost of doing business off the coast of U.S. (and maybe even the opportunity to do so at all) is definitely now in question.

Here's hoping that U.S. government sees reason and doesn't push their luck too far with BP. Like it or not, the U.S. oil industry is a significant part of our energy infrastructure, and the oil industry is a major source of jobs and state tax revenue in places like Texas and Louisiana. Seek justice by all means, but when it teeters over into populist vengeance and confiscatory retribution, the government may just find that it has made us all poorer in the long run.

Bottom line - I'd still be interested in stocks like Apache, Transocean, and Cameron. I still think BP survives this and works long-term as a stock, but you really have to have a strong stomach to step up today.

Allscripts + Eclipsys = A Deal That Makes Sense

A disturbing number of corporate M&A transactions end up being disappointing wastes of time and shareholders' money. In fact, I would go so far as to say that a lot of deals are about executive ego, hiding an inability to grow organically, or simply giving institutional shareholders the illusion that management is "active". 

I am putting all of that aside today. I actually do think that the combination of Allscripts (Nasdaq:MDRX) and Eclipsys (Nasdaq:ECLP) is one that makes a lot of sense. Accordingly, this may be one of the relatively rare deals that actually benefits all parties involved.  

For the full article:
http://stocks.investopedia.com/stock-analysis/2010/Allscripts--Eclipsys--A-Deal-That-Makes-Sense-MDRX-ECLP-CERN-GE-SI-ORCL-ATHN0609.aspx 

Review: Jihad

I apologize for being a little slow with any more reviews. Frankly, I have been spending a lot of time reading the books and not so much time thinking about writing up reviews. That said, I hope to be posting some on a more regular basis. And by all means, feel free to comment as to whether you find these interesting and useful or not.

I finished reading Jihad: The Rise of Militant Islam in Central Asia about two weeks ago. This book, by Ahmed Rashid, is a detailed account of how militant Islam has taken hold in several ex-Soviet states and countries like Afghanistan. There is a long and detailed account of how the Soviet system mistreated the people in this area, how the successor states have continued to oppress their people, and how that mistreatment and government-sponsored religious repression fueled a philosophy that is now causing so many problems around the world.



One of the more interesting aspects of the book is its treatment of the Taliban and its associated/affiliated organizations. Simply put, these people are not looking to create any sort of functioning state as we would understand it. Rather, they are looking to dominate the people living in what they believe is Islam's native ground and then spread their doctrine around the world. What's worse, they're are not looking to build a functioning state - their apparent goal and philosophy is to keep people in a medieval level of technology and government and focus existence entirely around religious life and preparation for the afterlife. In other words, if, when, and where the Taliban wins, life is going to be quite bleak by Western standards.

One downside to the book (and I do have to remember that it was written more than ten years ago) is that for all of its detailed explorations of how this mess started, it does not offer much in the way of what to do about it. Now, I do not necessarily cite that as a flaw of the author, for he may well have been intending only a journalistic/historical treatment of how radical Islam arose in this region. Still, it would be helpful to hear ideas about what can be done to root it and out and rehabilitate the people to whom radical and militant Islam appeals.

While this book is a bit old and many people may feel like they have heard all they want to hear about Afghanistan, Islam, and the Taliban, it is a quality read nevertheless. For those interested in a historical treatment and a "how did this all happen" narrative, this is a great book. For those more interested in current events and practical solutions, it may seem lacking.

Tuesday, June 8, 2010

Taking (Apart) Buffett At His Words

If I keep this up I'm not going to be allowed back home (Omaha).
By the way, there was a small misprint in the first sentence of the last paragraph. We'll be getting that fixed soon. 

On Wednesday, June 2, 2010, Berkshire Hathaway's (NYSE:BRK.A) CEO and chairman Warren Buffett, testified live in front of Congress's Financial Crisis Inquiry Commission. As much as I admire and respect him, I stubbed my eye more than once while reading the reports of his testimony. Here are some of the statements that really stood out. (Find out what makes the Oracle of Omaha so great in Warren Buffett: The Road To Riches.)


Why No Written Record?Warren Buffett elected not to provide any written testimony. Perhaps that is no big deal (he might have just been speaking extemporaneously), but it is notable for at least one reason - he was the only person to speak in front of the Commission that day to not offer written testimony. 

For the full text, please go to: 
http://financialedge.investopedia.com/financial-edge/0610/Taking-Apart-Buffett-At-His-Words.aspx

Monday, June 7, 2010

Ode to Joy Global

It is practically an investing meme now that investors should focus on the "pick and shovel" plays for major investment themes. I suppose you can take that advice very literally in the case of Joy Global (Nasdaq:JOYG), as this leading mining equipment company is very much a pick and shovel play on ongoing theme of global commodity exploitation.


The Quarter That WasAlthough Joy Global did not have a superb quarter at first glance, the context is important. Revenue was down 3% and operating income was down about 4%, but those results were significantly better than analysts expected. With equipment orders up about 43%, the backlog up by double-digits since the beginning of the year and a second straight quarter of a book-to-bill ratio above 1, there was no shortage of reasons to be pleased with the company's quarter.



For the complete article, please continue on to: 
http://stocks.investopedia.com/stock-analysis/2010/Ode-to-Joy-Global-JOYG-TCK-VALE-CNX-BUCY-IR-CAT0607.aspx

Friday, June 4, 2010

How Microsoft Lost Its Mojo

Please note that there was a typo in the original piece, stating that Ballmer became CEO in January of 2001. The correct date is January of 2000. 

With word last week that Apple Inc (Nasdaq:AAPL) is now the world's largest technology company, it is certainly appropriate to ask the next logical question: "What happened to Microsoft (Nasdaq:MSFT)?". Even more relevant to investors, though, is the question of whether or not Microsoft can fix its issues and once again become not only the biggest tech company, but a creative, growing force in the business.

What Went  WrongCriticism usually starts at the top, and I am OK with that - if you want to sit in the big chair and make the big bucks, you take the blame as well as the credit. Steve Ballmer was named CEO of Microsoft in January of 2000, a time that just so happens to almost perfectly correlate with Microsoft's stock reaching an all-time high in December of 2000.


The full article can be read at:
http://stocks.investopedia.com/stock-analysis/2010/How-Microsoft-Lost-Its-Mojo-MSFT-AAPL-GOOG-IBM-EMC-VMW-HPQ0604.aspx

Thursday, June 3, 2010

Buffett's Take On The Credit Crisis

I think I have reached the point now where nothing tied to the housing bubble, the credit crisis and the recession surprise me anymore. The capper was the testimony of Berkshire Hathaway's (NYSE:BRK.A) CEO Warren Buffett in front of Congress on Wednesday.

The Testimony

In his testimony, Buffett said that he did not believe that the CEOs of the credit ratings agencies deserve to be fired, and that the companies should not be criticized too harshly because they "made a mistake that virtually everybody in the country made."

Please read the full column at: 
http://stocks.investopedia.com/stock-analysis/2010/Warren-Buffetts-Take-On-The-Ratings-Agencies-BRK-MCO-MHP-WFC-BAC-GS0603.aspx 

Wednesday, June 2, 2010

FinancialEdge - Custom Budgeting For Young Adults

This is another personal finance piece that I wrote for Investopedia's FinancialEdge website. 

One of the best things about being a young adult is that you are starting fresh and you can finally decide how you want to live your life. Good decisions made here can make decisions later in life quite a bit easier.

The downside to being a young adult is that the mistakes made early in life can have long-lasting repercussions and lead to expensive "must-fix" situations down the road. One of the best ways to establish good habits and a good beginning to your financial life is to evaluate your spending and build a budget. (Your pals are great, but they may be leading you into financial trouble. Don't miss The No.1 Budgeting Tip For Young People.)

The full article can be read at:
http://financialedge.investopedia.com/financial-edge/0610/Custom-Budgeting-For-Young-Adults.aspx 

A New Dawn For Old Media?

The publishing world seems to be putting on an impromptu rendition of "Monty Python and the Holy Grail." First we had the scene with the Black Knight where the internet began dismembering old media and old media bravely told us "'tis but a scratch," as gouts of blood spurted out of the cash flow statement. Now, though, we may be to the scene with Eric Idle and John Young, in which Mr. Young bravely declares "I'm not dead yet!" 

What's Old is New AgainIronically, it may be new media and technology that ultimately saves the day for old media. As consumers continue to buy up the Kindle from Amazon (Nasdaq:AMZN) and competing devices like Barnes & Noble's (NYSE:BKS) Nook, Sony's (NYSE:SNE) Reader, and Apple's (Nasdaq:AAPL) iPad, it looks like publishers may have finally accepted the reality that their future is digital.  

For the full article, please go to: 
http://stocks.investopedia.com/stock-analysis/2010/A-New-Dawn-For-Old-Media-AMZN-BKS-SNE-AAPL-NYT0602.aspx 

Tuesday, June 1, 2010

Deepwater Horizon Disaster Just Keeps Getting Worse

I hope it doesn't sound too glib to categorize the latest developments in the Deepwater Horizon disaster as "... and the hits just keep on coming". What was already a bad situation for BP (NYSE: BP), Anadarko (NYSE: APC), Transocean (NYSE: RIG), and Halliburton (NYSE: HAL) just seems to be getting worse and worse.

As of Tuesday evening, it seems pretty clear that BP's efforts to stop the well from pouring even more oil into the well have failed. Making matters worse, the options left to BP are increasingly bad and the odds of success are increasingly long - a kill well has to be positioned with an extreme amount of precision and it will take quite a while to execute the procedure in the best of circumstances.

Making matters still worse (but probably not surprising those who have been watching this unfold), the U.S. government announced a criminal probe after the close. There's a pretty healthy list of laws and statutes that the government can site, including the Clean Water Act and an act designed to protect migratory birds. Now, the likelihood of anybody going to jail is vanishingly small, but the process does open up the possibility of even more financial punishment to the companies involved.

On top of that, a criminal probe gives the government more leverage in punishing the companies involved. In the process of a settlement, the government can reach for terms that otherwise would not likely be on the table in a simple criminal proceedings. As part of this, then, BP could face sanctions and restrictions on its ability to drill in U.S. waters.

It seems like the government is focusing on BP, Transocean, and Halliburton (those are the three companies that the government has told to keep records), but I would not give a free pass to Cameron (NYSE: CAM) or Smith Intl (NYSE: SII) just yet. After all, if and when it turns into a witch-hunt, anything that looks like a witch is going to get caught up in the mess.

I still believe in the long-term validity of the companies caught up in this man-made disaster. If you have a long enough time horizon, this is probably a very good time to buy shares in BP, Halliburton, Transocean, and Cameron. But there's no way of telling whether there's 20% more downside (or even more) as this all rolls out.

It's interesting (to me) to recall that Exxon (NYSE: XOM) shares really didn't fall that much in the wake of Exxon Valdez. In fact, if you look at a chart including a few years before and after the spill, you can't pinpoint the spill just from the stock chart. In contrast, the stocks of the companies involved in Deepwater Horizon have gotten pounded.

Long-term, there's not much that the government can (or will) do that would permanently impair the ability of these companies to prosper from ongoing appreciation in energy prices. If you can stomach the risk of seeing another 10-20% (or more) downside risk from here, these could be good buys today. But given how long this mess is going to drag out, you probably have plenty of time to accumulate the stocks.

Covidien Shuffles The Deck

One of the least-surprising take-outs I've seen was today's announcement that ev3 is getting bought out. That said, I'm not sure you could have found 10 people who would have put Covidien in the top three most likely buyers. Bard would have made sense to me, as well as Cook or even Boston Scientific or JNJ. But Covidien? 

Strange times... 

By the way, I do own shares of JNJ.

Medical technology companies, particularly the larger ones, tend to be quite acquisitive. So, another sign that normalcy may be returning to the economy and the market is when acquisitions start to tick up again. The good news is, this appears to be happening now. In the wake of the Medtronic (NYSE:MDT) and ATS Medical deal a little while ago, Tuesday saw the announcement of a larger deal between Covidien (NYSE:COV) and ev3 (Nasdaq:EVVV). 

For the full article, please continue on to:
http://stocks.investopedia.com/stock-analysis/2010/Covidien-Shuffles-The-Deck-COV-EVVV-MDT-CSII-SPNC-BSX-MEND0601.aspx 

Intuitive Surgical - Are Robots To Be Trusted?

It is a given that if you invest in stocks long enough, you will have a thick mental file labeled "Should'a, Could'a, Would'a." I typically do not give much mental time share to ruminating over what could have been bought, but one stock that does get my teeth grinding is Intuitive Surgical (Nasdaq:ISRG).  


Regardless of why I did not pull the trigger and buy the stock, it's worth investigating whether or not Intuitive Surgical has the right stuff to endure. Will it be a flash in the pan, or will it stay independent and become a future med-tech titan? 

The full article can be read at: 
http://stocks.investopedia.com/stock-analysis/2010/Intuitive-Surgical---Are-Robots-To-Be-Trusted-ISRG-HIT-SI-MDT-BSX0601.aspx 

As China Goes, So Goes The World?

I really like writing columns like this one ... where I get to poke and prod at the so-called "conventional wisdom".  It's always interesting to see what turns up when you challenge some basic assumptions.
 
Conventional wisdom is that China now calls the tune. You cannot read a commodity industry report without the assumption that China is the prime mover, and plenty of U.S. commentators have warned of the potential dire effects of a Chinese property bubble on U.S. equity markets.

But is this really true? Let's investigate. 

Calling the Tune on Commodities?On first examination, it would seem that the commodity folks have a point. After all, China is the incremental demand variable for a huge number of commodities. If you compare the iShares China 25 Index ETF (NYSE:FXI) to the iPath Commodity Index (NYSE:DJP), you see a pretty close correlation between the performance of the Chinese stock market and the performance of a basket of commodities. (For more, see Investing In China)

The full column can be read at: http://stocks.investopedia.com/stock-analysis/2010/As-China-Goes-So-Goes-The-World-FXI-VALE-BHP-INTC-WFMI-PFE0601.aspx.

Monday, May 31, 2010

A Market That Will Drive You To Drink

Amidst all of the gloom, doom and boom in the world these days, there is one inevitable constant. People drink. People drink to celebrate, to mourn, to console, to toast, and sometimes, just to pass the time. Though no business is truly immune to economic conditions, investors can look towards alcohol companies as a relative source of stability in very unstable times. 

Beer
AmBev
(NYSE:ABV), a subsidiary of Anheuser-Busch InBev (NYSE:BUD), is not only the dominant brewer in much of Latin America, but one of the most profitable beverage companies in the world. Ridiculously efficient, AmBev should benefit not only from leading brands, but the relatively low per-capita consumption in its markets. Investors will also be pleased to know that the company has to distribute at least a third of its earnings to shareholders in profitable years.  


Here's the full text of the column: 
http://stocks.investopedia.com/stock-analysis/2010/A-Market-That-Will-Drive-You-To-Drink-ABV-BUD-HINKY-LVMUY-STZ-DEO-CEDC0531.aspx 

Sunday, May 30, 2010

Book Review - When A Crocodile Eats The Sun

I've decided to periodically write a few book reviews here and there. Some of them will be business/investing-oriented, but I suspect that the majority will not.

So, the debut attempt will Peter Godwin's book When A Crocodile Eats The Sun.


Ostensibly, it's a memoir of the author's experience growing up in Zimbabwe and shuttling back and forth from his life as a journalist in places like New York and London back to his parents in Zimbabwe. Along the way, though, is plenty of commentary about the recent collapse of Zimbabwe, and that is ultimately what the book is really about.

This has been a topic I've followed closely for years, so most of the information in the book was not new to me, though it added in a lot of color and detail to what I thought I knew. Being well acquainted with the facts, though, doesn't really lessen the impact of hearing eye-witness accounts of them.

What the dictator Mugabe has done to the Zimbabwean people, and what the Zimbabweans have done to each other and themselves, is alternately infuriating, depressing, and numbing. I find it impressive, then, that the author maintains quite a bit of sympathy and patience for the people who in many cases turned on him and his family. He spares Mugabe little (and credits him for nothing), and that suits me fine. I suppose some apologists may find him patronizing and criticize his viewpoint as a privileged ex-pat, but I am not one of them.

It's an unfortunate reality that most people probably don't care enough about Zimbabwe to read a personal history of how it has fallen apart. Alas, that's almost always a part of the enabling process that allows dictators like Mugabe to do what they please.

In any case, I recommend this book for any interested Africa-watchers, as well as those who simply enjoy a good memoir. A word of warning, though - it's not light reading and there aren't very many happy interludes in the narrative.

Friday, May 28, 2010

Medtronic - Life In The Crosshairs

When you execute as well as Medtronic (NYSE: MDT) has over the years, when you become a leading company in virtually every market in which you compete, you get the dubious reward of being the company everyone else wants to knock off the mountain. So far, though, Medtronic management continues to demonstrate that it is capable of taking a huge business and making it even bigger. 

The Quarter That Was 
Medtronic reported its fiscal fourth quarter results May 25. As has been the case of late, the results were "good ... but not great". Revenue was up about 6% in constant currency terms, and that was more or less in line with expectation. Likewise, bottom-line earnings per share were up 9% and two pennies higher than the average analyst estimate.  

For the full article:
http://stocks.investopedia.com/stock-analysis/2010/Medtronic---Life-In-The-Crosshairs-MDT-BSX-STJ-ZOLL-NUVA-CFN-EW0528.aspx

Please note, the editor of the piece made a small error in spelling out St. Jude as "Saint Jude".

Insurers Caught In The Spill

Cleaning up the mess left in the wake of the explosion and sinking of the Deepwater Horizon is going to be a multi-part process. BP is doing its part, trying to stop the shattered well from dumping even more oil into the Gulf and cleaning up what has already come out. Looking ahead, though, there will also be a major role for the insurance industry to play, as it is often insurance companies that bear the brunt of the financial ramifications of accidents like Deepwater Horizon. 

Cost Estimates Are Starting To Come Ashore
All told, the most common estimates floating out there for total insurance industry exposure to the Deepwater Horizon event range from about $1.5 billion to $3.5 billion. Should the bulk of the spill stay at sea, the losses will probably be on the lower end of the range. Should the oil come ashore in large quantities, though, it is likely that various business interruption policies will be triggered, pushing up the costs to the industry.


So far, a host of companies have come forward with their initial assessments of liability.

For the full article, please continue on to: 
http://stocks.investopedia.com/stock-analysis/2010/Insurers-Caught-In-The-Spill-PRE-XL-ACGL-ACE-WRB-RIG-CAM0528.aspx

What ASCO Can Tell You About Biotechs (Pt 3 of 3)

Although this article shares the same two intro paragraphs as the other two ASCO pieces, it discussing a whole separate list of biotechs. I promise!
 
One of the major biotech events of the year is fast approaching. The annual meeting of the American Society of Clinical Oncology (ASCO) will take place in Chicago from June 4 to June 8. This event is like Woodstock for biotechnology - if Woodstock were clean, air-conditioned, and had plenty of restrooms. If you invest in biotechs or pharmaceuticals that want to play in the huge and well-reimbursed world of oncology, this is one of the major events of the year. 

Ahead of the meeting, ASCO releases a list of abstracts that scientists and companies will present. In some cases, these abstracts give away at least most of the story (efficacy, safety, etc.), while other abstracts are embargoed until the meeting itself. In any case, investors can still look forward to follow-up data (abstracts are submitted well ahead of the meeting) and often the amount of attention garnered by a presentation reflects overall interest in the compound.

Here we present some of the companies presenting abstracts at ASCO.

For the full article, please go to: 
http://stocks.investopedia.com/stock-analysis/2010/What-ASCO-Can-Tell-You-About-Biotechs-CELG-DCTH-RHHBY-ZIOP-ZGEN0528.aspx 

Thursday, May 27, 2010

Reposting - Great Dividend Payers In Medical Technology

I just found out that the original link for this article wasn't working. 
Here's is a reposting. Apologies for the inconvenience!

There are a lot of solid reasons for investors to include medical technology stocks in their portfolios. The healthcare sector has grown faster than the economy and seems poised to continue to do so, and the more established names in this field routinely post excellent returns on capital. Better still, medical technology is generally spared the feast-famine cycle of patent expirations that bedevil the pharmaceutical sector. 

Now we can add another reason to like medical device stocks - dividends. As many investors already know, the stocks of companies that pay dividends tend to outperform those that do not. When you combine the advantages of dividend-paying stocks with the advantages of medical technology stocks, you have a powerful mix.

Full text at:
http://stocks.investopedia.com/stock-analysis/2010/Great-Dividend-Payers-In-Medical-Technology-ABT-BAX-MDT-BDX-BSX0521.aspx  

Apple Now King of the Mountain

Yesterday marked an event that probably no sane person would have predicted 13 years ago - Apple (Nasdaq:AAPL) surpassed Microsoft (Nasdaq:MSFT) and became the company with the highest market capitalization of any tech company in the world. While the margin of superiority is tight enough that leadership could change hands a few more times, it is probable that Apple is going to enjoy a stretch of time as the most valuable tech company in the world. (For a quick refresher, check out Market Capitalization Defined.)

How Did This Happen?If you go back to 1997 when Steve Jobs rejoined the firm, Apple was nearly bankrupt and WinTel ruled the technology world. Although the PowerBook proved popular, the Macintosh was floundering and the company wasted a great deal of time and money on the Newton platform and a failed alliance with IBM (NYSE:IBM) and Motorola. Enter, or rather re-enter, Steve Jobs. (To read more about Steve Jobs' influence, see What Would Steve Jobs Do? and Hype It Like Steve Jobs.)

For the rest of the article, please go to: 
http://stocks.investopedia.com/stock-analysis/2010/Apple-Now-King-Of-The-Mountain-AAPL-MSFT-IBM-GOOG-BIDU-HPQ0527.aspx  

Monsanto - I Should Have Known Better

I really have been doing this too long to excuse this screw-up.

In my experience, companies that lower guidance generally don't just do it once or twice before they hit bottom and resume their prior trend. Disappointments often come in threes (or more) and it takes time for a management team to root out and address whatever it is that went wrong in the first place. And yet, like some newbie investor, I rushed in to buy Monsanto (MON) after its recent underperformance and disappointing guidance. 

Pretty much from the moment I clicked "Execute", the stock has gone down. Today I get my just desserts in that the company is lowering guidance yet again, and the stock is taking another punch to the gut.

If there is any good news here, and there really isn't, it's that the disappointment is coming from the company's glycophosphate (weed killer) business. This business is far more cyclical than the company's larger seed traits business, it's more of a commodity business, and it has been an underperformer in recent times. On top of all that, reports have been coming out in recent months that glycophosphate-resistant weeds are emerging in the Southern U.S. (as if we don't have enough trouble with kudzu!).

So although this news hurts the company's near-term financial performance, it doesn't change a thing about my long-term thesis on the stock. Simply put, Monsanto is a leader in next-gen crop research, and I believe this is one of the best sectors to be for the long-term. True, DuPont (DD) and Syngenta (SYT) both seem to be getting their "stuff" together and closing the gap on Monsanto (especially Syngenta here of late), but I think Monsanto is still positioned to be the long-term leader in this field.

I'm likely setting myself up for more near-term underperformance, but I'm grudgingly hanging on to my shares. I think most of the bad news is now priced into the stock and I think the company is more or less "clearing the deck" in terms of its forecasting. Like I said, my long-term thesis on this company hasn't changed, so I don't feel any compulsion to sell quickly and move on.

Since I have the advantage of not having a boss or investors to answer to, I might as well make the most of it and not be shaken out of a stock where I still have long-term conviction.

In the meantime, I'll just feel stupid for a little while and then move on to the next crisis.

ASCO - A Big Deal For Biotechs (Pt 2)

This is the second of three articles previewing the ASCO meetings in Chicago next week.

One of the major biotech events of the year is fast approaching. The annual meeting of the American Society of Clinical Oncology (ASCO) will take place in Chicago June 4-8. This event is like Woodstock for biotechnology - if Woodstock were clean, air-conditioned and had plenty of restrooms. If you invest in biotechs or pharmaceuticals that want to play in the huge and well-reimbursed world of oncology, this is one of the major events of the year.

Ahead of the meeting, ASCO releases a list of abstracts that scientists and companies will present. In some cases, these abstracts give away at least most of the story (efficacy, safety, etc.), while other abstracts are embargoed until the meeting itself. In any case, investors can still look forward to follow-up data (abstracts are submitted well ahead of the meeting), and often the amount of attention garnered by a presentation reflects overall interest in the compound. (For more, see Stocks On Drugs: What It Takes To Get High.)

To read the full text of Part 2, please continue on to: 
http://stocks.investopedia.com/stock-analysis/2010/ASCO---A-Big-Deal-For-Biotechs-BMY-ARIA-ARQL-KERX-AEZS-NKTR-VNDA0527.aspx 

Wednesday, May 26, 2010

A Big Deal For Biotechs - ASCO

One of the major biotech events of the year is fast approaching. The annual meeting of the American Society of Clinical Oncology (ASCO) will take place in Chicago from June 4 to June 8, 2010. This event is like Woodstock for biotechnology - if Woodstock were clean, air-conditioned and had plenty of restrooms. If you invest in biotechs or pharmaceuticals that want to play in the huge and well-reimbursed world of oncology, this is one of the major events of the year. 

Ahead of the meeting, ASCO releases a list of abstracts that scientists and companies will present. In some cases, these abstracts give away at least most of the story (efficacy, safety, etc.), while other abstracts are embargoed until the meeting itself. In any case, investors can still look forward to follow-up data (abstracts are submitted well ahead of the meeting) and oftentimes the amount of attention garnered by a presentation reflects overall interest in the compound.

Here we present some of the companies presenting abstracts at ASCO. 

For the full article, please continue on: 
http://stocks.investopedia.com/stock-analysis/2010/A-Big-Deal-For-Biotechs---ASCO-AMGN-PFE-CLDX-PCYC-ITMN0526.aspx


 

Can Apple Stay Fresh?

Me writing a positive story on Apple ... Folks, check your local farms to see whether there are any reports of flying pigs today. 

I've recently read that Katy Huberty, an analyst at Morgan Stanley, has put a price target on shares of Apple (Nasdaq:AAPL) of between $310 and $400. For those of us who remember the tech bubble, there may be a shiver of remembrance at the $1,000 price target put on Qualcomm (Nasdaq:QCOM) by a PaineWebber analyst in late 1999. That pretty much marked the beginning of the end to that run. The question is, does this signal a similar high-water mark for Apple? 

For the full article, please continue on to:
http://stocks.investopedia.com/stock-analysis/2010/Can-Apple-Stay-Fresh-AAPL-QCOM-NOK-DIS-AMZN-GOOG-HPQ0526.aspx

Tuesday, May 25, 2010

Buffett Scandals - Then and Now

This was an interesting piece for me to write. I've long admired Buffett, and I wasn't entirely sure it was a project I wanted when it was first suggested to me. Now that I've written it, though, I find it interesting to see that Mr. Buffett really has kept his nose clean for the most part. What controversies there have been have largely been due to the actions of other people. To his great credit, though, Buffett seems to realize that when you sit in the big chair, you take the credit *AND* the blame when things go wrong, whether you have much to do with matters or not. A lot of CEOs should learn from that example. 

It is a peculiar American trait that we celebrate stories about the "land of opportunity," yet we also take a perverse pleasure in plastering bulls eyes to the backsides of the very wealthy. As one of the wealthiest people in the world, it is no surprise that the much-heralded investor Warren Buffett has had his share of controversies over the years.

The latest PR crisis for the Berkshire Hathaway (NYSE:BRK.A) CEO is his investment in Goldman Sachs (NYSE:GS) and his ongoing public support for the company and its management.

No one has thus far accused Buffett of any wrongdoing, beyond continuing to support a management team that is quite unpopular at present.

For the full article, please continue to: http://financialedge.investopedia.com/financial-edge/0510/Buffett-Scandals-Then-And-Now.aspx

Auto Parts Could Rev Up Returns

Reports of the death of the auto industry have been greatly exaggerated.

American automakers are certainly still in trouble, but there is a wide world out there and people, especially Chinese people, continue to buy cars. If people are still buying cars, that means companies are still building cars. If companies are still building cars, that means there is still business out there for auto parts companies.

Back From the DeadInvestors are right to be skeptical of the thesis that there is actually money to be made from investing in auto parts stocks. After all, many of these companies had the same problems as the U.S. automakers - stagnant sales, competition from foreign companies, outdated (and excessive) cost structures and too much debt. More than a few companies went bankrupt or flirted with bankruptcy.  (For more, see Analyzing Auto Stocks.)

For the full article, please continue on to: 
http://stocks.investopedia.com/stock-analysis/2010/Auto-Parts-Could-Rev-Up-Returns-ALV-GNTX-SORL-TXIC-ARM-AXL-TEN0525.aspx 

Monday, May 24, 2010

Transocean Still In The Crosshairs

The hits just keep on coming for deepwater driller Transocean (NYSE: RIG). Today word came out that a gaggle of senators (I believe they're are all senators ... maybe there is a rep or two in the mix) sent a letter to the Attorney General asking him to investigate Transocean's recent  special dividend announcement.

The dividend, about $1 billion in total, was going to be paid in four quarterly installments. According to these business geniuses, they are concerned that the payment of such a dividend could make it difficult to pursue liability claims against Transocean in the future.

Here I would explain the logic of this move ... if there was any.

So much for "innocent until proven guilty", huh? Moreover, these economic geniuses apparently don't realize that Transocean has been cash flow positive for nine straight years and given the dynamics of the energy market and deepwater drilling, I really don't see that reversing any time soon.

I don't know whether or not Transocean has done anything that will stand up as legal liability. And nobody else does either (possibly including Transocean). Maybe Halliburton flubbed the cementing. Maybe Smith's fluids were faulty. Maybe Cameron's blowout preventer was faulty, or maybe the accident was one not anticipated by the design of the device.

That's a lot of "I don't knows" or maybes.

Practically speaking, Transocean is likely going to get stuck for some part of the bill -- whether through proper legal decisions or through political maneuverings aimed at "punishing" these nasty energy companies. Given today's letter, that latter contingency shouldn't be discounted by investors. While there are certainly limits on what the government can do, some of those limits are imposed only at the level of the Supreme Court and that's a long, expensive journey for any company.

Even still, Transocean isn't likely to be bankrupted by this. Short of foolish and criminal negligence (namely, not properly maintaining equipment like the BOP), I just don't see the smoking gun that keeps Transocean on the hook. That doesn't mean, though, that lawyers and politicians won't try sticking it to them in the meantime.

You have to a pretty high threshold for pain to buy today, as the press isn't likely to get better any time soon. Still, though, the stock is trading for a lot less than I believe it's fundamentally worth and those situations always appeal to me.

Friday, May 21, 2010

Great Dividend Payers In Medical Technology

This was posted late today on Investopedia. 
I would clearly have included Johnson & Johnson (JNJ) in the list, if not for the fact that Investopedia does not allow writers to even mention stocks they own. I do own shares of JNJ.

Here is the article: 

There are a lot of solid reasons for investors to include medical technology stocks in their portfolios. The healthcare sector has grown faster than the economy and seems poised to continue to do so, and the more established names in this field routinely post excellent returns on capital. Better still, medical technology is generally spared the feast-famine cycle of patent expirations that bedevil the pharmaceutical sector.  

Now we can add another reason to like medical device stocks - dividends. As many investors already know, the stocks of companies that pay dividends tend to outperform those that do not. When you combine the advantages of dividend-paying stocks with the advantages of medical technology stocks, you have a powerful mix.

For the full article, please continue on to: 
http://stocks.investopedia.com/stock-analysis/2010/Great-Dividend-Payers-In-Medical-Technology-ABT-BAX-MDT-BDX-BSX0521.aspx 

Personal Rant - A Memo to BP Complainers, "Pick Your Poison"

It seems to me that bashing BP is now a cause celebre amongst the chattering class. The way some of these people are talking, you would think that BP laid explosives around the drilling rig and deliberately blew it up just to dump oil in the Gulf and ruin the lives of all these people.

Enough already.

Yes, BP screwed up. Yes, BP management has been irritatingly clumsy in their PR response. Do you think they wanted to dump thousands of barrels of valuable oil into the Gulf? Do you think it is easy to fix a blow-out deep below the sea? Do you think there is a manual for this?

I wonder how much of this reaction is a byproduct of what I have long called the "me wantee" culture in America. We want everything to go our way; we want our cake, we want to eat it, and we want it to have 100% of our daily vitamins without any calories.

People need to wake the hell up and realize that modern life has its costs. You want to stop drilling offshore? Really? Where do you want to get your oil from? The tar sands of Canada? Off the coast of Angola? From Russia?

Producing oil is a dirty business and occasionally things go wrong. That's just a fact of life. Is the oil from tar sands or Angola better because it degrades the environment in Canada and Angola instead of ours? Is it "better" because we don't have to live with the risk or see the costs?

Or what about hybrid and electric cars? Are these kosher because Americans don't have to see the environmental degradation and human exploitation that goes with digging up the rare elements that make up the batteries and components? Are toxic mine tailings not a problem as long as they don't hurt "our people"?

There are no free rides here. If you want to live in a modern economy, you have to make unpleasant choices. If you want electricity, it has to come from somewhere. It isn't practical to provide America's energy needs from solar, wind, geothermal, hydroelectric or other "fluffy bunny-safe" technologies. So choose from coal, gas, oil, and/or nuclear - every one of them has problems. Pick one.

If you want a modern economy, you need fuel for transportation, certain metals for technology, and materials like plastics. Those come from mining, drilling, and refining. Want to replace all of that with corn? Fine … then you pick who gets to starve when we reallocate grain production to fuel/plastics instead of food. So take your pick - spills, mine disasters, refinery pollution, etc. or starvation.

Or maybe we should all just live like the Amish. Anybody want to buy a buggy?

I sometimes feel like the modern manifesto goes something like this. " I want an SUV, $1/gal gasoline, and no environmental worries. Oh, and I want a diamond ring ... but the diamond has to be harvested by fluffy bunnies and the gold has to come from renewable unicorn droppings."

I am not trivializing the huge costs and impact of this oil rig disaster in the Gulf. It's serious, a lot of people are getting hurt, and the clean-up is going to be long, painful, and expensive. I'm not mocking those who are, or will be, suffering as a result of this. I am not mocking people who are legitimately concerned about the environment and working to find solutions.  But people need to rein in the hyperbole and realize that adult life in the modern world requires some tough decisions and the realization that nothing comes for free.

Thursday, May 20, 2010

TiVo Gets Scrambled

Do not count your chickens (or lawsuit settlements) before they are hatched. That would seem to be the lesson to TiVo (Nasdaq:TIVO) shareholders from a surprising court decision on Friday, May 11. Due to a federal appellate court's decision to re-review the company's case against Dish Network (Nasdaq:DISH), the stock lost almost half of its value in a single day.

What a Long Strange Trip It Has BeenTiVo is largely credited for the development of digital video recorders (DVR), one of the more popular add-ons for most dedicated TV-watchers. While TiVo sells its services directly, they also partner with companies like DIRECTV (NYSE:DTV) and Comcast (Nasdaq:CMSCA) to sell these services.

For the rest of the article: 
http://stocks.investopedia.com/stock-analysis/2010/TiVo-Gets-Scrambled-TIVO-DISH-DTV-CMCSA-VZ-T0520.aspx 

Unwrapping The Home-Improvement Big Boxes

Now that the "great retrenchment" in consumer spending has been going on for a couple of years, are shoppers itching to cast aside survivalist shopping at Wal-Mart (NYSE:WMT) and return to the likes of Home Depot (NYSE:HD) and Lowe's (NYSE:LOW) to buff up their houses? 

Although one quarter does not prove a thing, Home Depot and Lowe's both did something this week that they have not done in almost four years each - they posted positive same-store sales growth for a full quarter. Perhaps, then, this is the renaissance of two of America's most successful retail concepts.  

For the full article, please continue on at: 
http://stocks.investopedia.com/stock-analysis/2010/Unwrapping-The-Home-Improvement-Big-Boxes-HD-LOW-WMT-TSCO-SHLD0520.aspx

Wednesday, May 19, 2010

Much Ado About the Wrong Thing

It is no great surprise to me anymore when I see the popular financial media overstate the importance of the goings-on of the equity market and all but ignore what is going on in the credit markets. But this latest example irks me all the same.

The markets have been chaotic lately, the papers tell us, because of Germany's decision to implement a limited ban on naked short selling. That may be true ... but it is only part of the story.

**To keep this sort-of brief, I'm going to footnote a discussion of shorting. Those who know about naked shorting can just continue on and not worry about it.


The news coverage of Germany's decision focused on the fact that a limited number of equities in the financial services sector are on the list. Big deal. We in the U.S. banned shorting altogether in some financial services stocks for a time during the worst of the credit crisis and it was not the end of the world. I really do not believe the markets here are selling off because of this announcement; it is small potatoes.

What is a bigger deal, though, is the fact that the naked short ban includes government bonds and credit default swaps. I cannot tell you in exact numbers how significant that is, in part because there is no clearinghouse for these instruments like there is in equities. I can tell you anecdotally, though, that naked shorting is a big part of how CDS trading is done and it is not uncommon in bonds either.

Basically, then, Germany has unilaterally re-written some of the rules of the credit market, and the credit market is far larger than the equity market. That, in turn, can mean chaos for the big trading desks at Goldman Sachs (GS), Bank of America (BAC), Citigroup (C), JPMorgan (JPM) et al. Yet another shot across the bow and shock to the system for these huge financial companies is not good news for the market.

So, ultimately I guess the papers have it right - the short ban is likely behind a lot of the turbulence in the markets. But the "how" really has nothing to do with the ban on naked shorting of equities. Once again, the financial press just misses the story when it comes to the credit market.

**For those who do not know, naked short selling is essentially selling something short with no attempt to locate and borrowing the asset. Normally, when somebody wishes to short an asset (like a stock), their broker finds those shares and borrows them for the would-be shorter. In that arrangement, you never have more than 100% of a company's shares sold short (and practically it will never be 100% because certain holders cannot or will not loan out shares to be shorted).

With naked shorting, no attempt is made to locate and borrow the assets. So, you could theoretically have 200% of a company's shares sold short in the market. Clearly, allowing naked shorting allows for almost unlimited selling pressure, though it works both ways and those shorts eventually have to be covered unless the asset goes to zero.

Although naked shorting in the U.S. equity markets got a lot of attention a few years ago (mostly due to Overstock.com (OSTK) and its very vocal CEO), it is generally not a problem. It is not supposed to be permitted to anybody except market makers, and it serves a legitimate purpose in keeping a liquid market. If a market maker cannot perform a naked short, it can essentially gum up the works and impair trading.

Disclosure - I own shares of JPMorgan

A Good Piece ... That I Didn't Write

I wanted to include a link here to this piece on FinancialEdge by Liz Davidson. 


http://financialedge.investopedia.com/financial-edge/0510/How-To-Parent-Your-Aging-Parents.aspx

Tuesday, May 18, 2010

Keep An Eye On Biobutanol

This article actually was originally prompted by something I read in my weekly reading of newspapers, magazines, and journals. I just wish I could remember which one it was... 

Few topics seem to garner as much interest these days as the idea of moving past the gasoline-based transportation economy and onto something better. Several candidates for "better" have risen and fallen in recent years - fuel cells and ethanol seem to be yesterday's news - and advanced batteries are the belle of the "better" ball right now.

Investors should keep an eye out for biobutanol. While there are several significant challenges to surmount before biobutanol could be commonplace, this is an alternative fuel that may actually give us a real alternative when it comes to fueling our cars. That, in turn, could deliver real rewards for companies like DuPont (NYSE:DD), BP (NYSE:BP) and Total (NYSE:TOT) down the line.

http://stocks.investopedia.com/stock-analysis/2010/Keep-An-Eye-On-Biobutanol-DD-BP-TOT-F-HMC-CZZ-ADM0518.aspx  

Recovery Rides In On The Rails

This piece was posted early this morning on Investopedia. 
http://stocks.investopedia.com/stock-analysis/2010/Recovery-Rides-In-On-The-Rails-UNP-CP-CNI-NSC-CSX-BTU0518.aspx 

I strongly recommend Rail Times Indicators; it is an excellent source of information on what's going on with North American railroads.

If you really want to know what is going on in the economy, you cannot just look at the flashy headline economic data that comes out every month. You need to know what is happening at the "street level", and that is why I am a fan of following railroad traffic data.

According to data produced by the American Association of Railroads (in its monthly Rail Time Indicators report), U.S. carloads jumped almost 16% from the year-ago level and hit their highest number since November 2008. Likewise, Canada was quite strong - carloads jumped almost 27% annually and ended up at a level not seen since October 2008.

The rest of the article can be read at Investopedia: 
   http://stocks.investopedia.com/stock-analysis/2010/Recovery-Rides-In-On-The-Rails-UNP-CP-CNI-NSC-CSX-BTU0518.aspx

Monday, May 17, 2010

Does A123 Have The Juice?

Investing in potentially game-changing technology comes at a cost. By the time you know the winners from the losers, a large percentage of the gains are already in the hands of those investors who stepped up when there were more doubts than answers. On the other hand, investing in these companies is a virtual guarantee of volatility and runs a serious risk of capital loss. 

All that said, battery maker A123 (Nasdaq:AONE) in one of those plays that may be worth the risk. Although the stock has been weak lately and first-quarter earnings will not help matters, these are still early days for the company, the technology, and the industry as a whole.  

For the full text of the article: http://stocks.investopedia.com/stock-analysis/2010/Does-A123-Have-The-Juice-AONE-BLDP-SWK-JCI-HEV0517.aspx

Thursday, May 13, 2010

A Few Fruits From This Week's Research

When you're a stock junkie (to say nothing of a financial writer), you're pretty much always doing stock research. Sometimes you go a while before finding good ideas, and then sometimes you find them in bunches.

This week turned up a few interesting tidbits, as I was looking mostly at the chemicals sector.

Goodyear (GT) - Analysts seem to like this one, and it was up more than 10% in the past week. But a tire company? Really? Sure, the EV/EBITDA ratio isn't bad, but this company's historical ability to produce real returns (ROIC) isn't very good.

Aceto (ACET) - I like the idea of a company that makes the chemical underpinnings of pharmaceuticals, particularly generics. By and large, these guys don't mess with the legal patent wrangling like a TEVA. The EV/EBITDA is on the high side, but this one looks interesting.

Calgon Carbon (CCC) - Wow. Great business and decent returns on capital, but a pretty poor long-term record of growth and doesn't look at all cheap to me (though the analysts seem to like it well enough).

Hexcel (HXL) - Nice story (carbon fiber for Boeing and Airbus), but I can't even get close to making this one work on a valuation basis.

Lubrizol (LZ) - Am I the only one who didn't know this company was producing double-digit ROICs, good growth, and a strong free cash flow yield? Unfortunately, as much as the company looks like a winner, the stock seems to be there already.

Metabolix (MBLX) - You either win big or lose big. It's a nice idea, making plastics out of corn, switchgrass, and the like, but valuation is an exercise in faith. Treat it like a biotech. I probably should go back and double-check the IP here, because that will be the real deciding factor.

Methanex (MEOH) - I was shocked at how cheap this one looks when I value it by a forward EBITDA basis. It's been a volatile commodity business in the past, but they have a lot of unused capacity (good for margins if volumes go up) and China seems poised to use a lot more methanol.

Sigma Aldrich (SIAL) - Great company. No bargain in the stock, though.

Huntsman (HUN) - Hmmm. This one could be interesting. It's a diversified chemicals business, but a little less commoditized than your average commodity business. This one could be worth a closer look.

Landec
(LNDC) - This was a popular "little known" growth stock a few years ago. It was supposed to be a company that "looked like a commodity business, but really wasn't". Guess what? It was. At least enough to knock the wind out of its sales. I'm intrigued, though, and if my numbers are right this could be a cheap one.

And so ends the gleanings from this week's research. There were a lot more names I looked at, but I feel like 10 at a time is about all anybody wants to read about.

Happy hunting!

An Increasingly Small World For Disney

Sometimes, conventional wisdom is not so wise. Take the case of media giant Disney (NYSE:DIS) - the conventional wisdom is that the popularity and ubiquity of its brands (and its eternal appeal to kids) insulates it from economic conditions. That so-called wisdom bypasses the reality that it takes money to go to theme parks, advertising on networks trails off in recessions and movie production requires large upfront investments for uncertain returns. 

Diversification Shows its AdvantagesThat said, Disney's diversified asset base has helped the company weather the downturn in relatively good order, and this quarter was another example. Revenue rose about 6% overall as strength in the cable and film business offset pretty iffy results in broadcast TV and theme parks. Margins likewise have stayed strong, even as the company lays out significant money for programming rights for ESPN. One note of caution on the margins, though. Successful movies like Alice in Wonderland can certainly boost profitability, but seemingly every studio has a dry spell from time to time and they are inherently impossible to predict (few studio execs would green-light a movie they know is doomed to fail).  

http://stocks.investopedia.com/stock-analysis/2010/An-Increasingly-Small-World-for-Disney-DIS-CMCSA-GE-CBS-NWS-FUN-VIVDY0513.aspx

Will Adaptive Design Change the BioPharma World?

I wrote the following for Investopedia, and it was published today. 
I'm actually pretty interested in seeing what, if any, reaction I get to this. I really do believe this is one of the bigger ideas that could emerge in biopharma over the next few years, but it is an idea that you scarcely hear about outside of occasional panels and forums at industry conferences and meetings. 

I hope you find it interesting. 

Every so often a good idea comes out way ahead of its time. Fuel cells actually predate the gasoline engine, the Apple (Nasdaq:AAPL) Newton is the almost-forgotten iPad/iPhone predecessor, and Nikola Tesla sketched out plans for concepts like wireless energy transfer and airplanes that could take off vertically in the 1920s.  

Adaptive clinical trial design may ultimately belong on this list as well. Although the idea of changing pharmaceutical drug trials in response to data generated within the trial has been around for at least 10 years, the idea may finally be on the cusp of being realized. Should this concept become more commonplace, it could be a major step forward for biotechnology and pharmaceutical companies.

Read the full column at: 
http://stocks.investopedia.com/stock-analysis/2010/Will-Adaptive-Design-Change-The-BioPharma-World-AMGN-GILD-ITMN-EXEL-LLY-PFE-PRXL0513.aspx  

Wednesday, May 12, 2010

A Private Deal For Sequenom

Interesting little deal today in the diagnostics space.  

Sequenom (SQNM) announced a private placement of 12.4M shares at a price of $4.15/sh ($51.6M total). The company definitely needs the cash to continue its R&D program, and the size of this deal should calm the funding fears for a while.Still, I can't help but notice that the investors in this deal demanded a pretty substantial discount to the prevailing stock price - nearly a 25% haircut to today's opening price.

To me, that seems like a pretty fair discount given the concerns and controversy around this company. There are plenty of places where you can read about the details, but the gist of it is that a major scandal hit the company last year; costing most of the sr. mgmt their jobs, costing the company several lawsuits, and throwing into question whether or not the company's lead test even works. On top of that, I'm still under the impression that the owner of the underlying technology (who had extended SQNM a license) wants out of that agreement.

So, in other words, this is a $340M market cap company trading basically on the hope that their test for Down's Syndrome works (but where the past data is all but useless because of the possibility of deliberate bias in prior studies) and that they still have the rights to develop and market it. Given all that, then, a 25% discount is not an unreasonable margin of safety.

On a more positive note, the company gave pretty clear guidance last week regarding the development timeline for this test, with test optimization expected to be over by the end of Q3'10, testing of samples conducted in the fourth quarter, and commercial launch by the end of 2011.Now, maybe I'm reading too much into this, but doesn't this sound a bit like "back to the drawing board?" If  they're having to go back to test optimization, that suggests to me that there were at least a few significant flaws in the old test. Whether that completely invalidates the old promise or not, I do not know. Unfortunately, I don't think anybody outside the company knows either, so it's basically an exercise of faith at this point.

I happen to think that the baseline technology the company is using is pretty sound, and I think there's some real market potential for this test. But with so many other options to chose from, and options that offer "clean" stories, I just don't see the need to take the risk here right now.

Good Luck, Peter

Saw an announcement after today's close that Peter Donato has resigned from his position as CFO at IRIS International. I had the pleasure of interacting with him a number of times while I covered his company as a sell-side analyst. Much as it pains me to praise any fan of Ohio State and the Detroit Redwings, I always enjoyed interacting with Peter, and IRIS is poorer for his departure.

I won't even begin to speculate as to why he is leaving the company and what it may, or may not, mean. People move on in business and it's just a fact of life. Still, it's another ripple through a company that seems to be pretty much cursed with them. Given what the company hopes to accomplish in the near term - filing for VELOCITY, securing FDA approval for ProsVue, launching those two products in the US, and rebuilding the company's reputation with the Street -- that is a pretty significant shake-up for the company.

I guess the "good news" here for an IRIS shareholder is that the value of the stock is pretty much based upon what the company *should* be able to do and not what it has been doing recently. Accordingly, assuming that the company recruits a qualified candidate, it shouldn't really impact the story over the long-term. Still, I would be nervous about what this management shake-up is going to do to the company's launch plans.

Again, best of luck Peter!

Has Europe Risen To The Challenge?

This is a bit out of date now, as it seems like the market has more or less digested the ECB rescue package and deemed it "good enough ... for now".

After seeing punishing increases in interest rates, declines in the euro and chaos in the equity markets in response to slow and unsteady action on Greece, the ministers of the European Union decided to try to get ahead of the next round of worry and launch a massive liquidity measure for its members. The announced package immediately sent the euro higher along with equities of all stripes, but especially those exposed to the financial chaos in Europe.

What HappenedEarly on Monday morning, the finance ministers of the EU announced an enormous liquidity package designed to restore faith in the euro and the solvency of its members. The three-part program is worth almost $1 trillion and it consists of 60 billion euros in loans, 440 billion euros in future loan guarantees and as much as 250 billion euros in funding from the IMF.
  
The full column can be read at: http://financialedge.investopedia.com/financial-edge/0510/Has-Europe-Risen-To-The-Challenge.aspx

Meaty Results From Zhongpin and Tyson

These are pretty fat days to be in the protein business. Corn and soy prices, the two primary feed ingredients, are about as low as they have been in a few years, while prices for hogs and cattle are quite high. That margin, which goes by the somewhat grizzly name of "crush spread", is music to the ears of major meat producers like Tyson Foods (NYSE:TSN), while China's Zhongpin (Nasdaq:HOGS) also continues to see a benefit from ongoing economic development in its home country. 

http://stocks.investopedia.com/stock-analysis/2010/Meaty-Results-From-Zhongpin-And-Tyson-TSN-HOGS-SFD-MCD-YUM-PEP-KFT0512.aspx

Penn Virginia Turning Coal Into Cash

Penn Virginia has been one of my favorite companies for a while, and it's a company that I have written about a lot over the years. Oddly enough, I've never actually pulled the trigger and owned it in my own portfolio. Maybe soon, though...

Say you want to invest a portion of your portfolio in coal, America's dominant energy source for electricity, but you also want to get a hefty stream of income from that investment. Unfortunately for dividend-seeking investors, the leading names in the coal industry like Peabody Energy (NYSE:BTU), Arch Coal (NYSE:ACI) and  Massey Energy Co. (NYSE:MEE) do not pay especially large dividends. What do you do?  

Well, you could try to buy a share in a coal mine lease, but that is quite frankly not an option for most regular people. You could also pursue a covered call writing strategy, but that may be a bit too much work for some investors. Or, you could also just buy the shares of a royalty partnership like Penn Virginia Resources (NYSE:PVR). 

http://stocks.investopedia.com/stock-analysis/2010/Penn-Virginia-Turning-Coal-Into-Cash-PVR-BTU-ACI-MEE-RRC-EOG-ARLP-NRP0512.aspx  

Tuesday, May 11, 2010

Earnings From a Couple of Gas Giants

There is an argument out there that closely analyzing the quarterly financial performance of energy companies is basically futile. The impact of energy prices is so significant, the thinking goes, that it renders the company-specific details basically meaningless. 

But if you look at long-term charts of the players in the energy space, you will see that the stocks of efficient and savvy producers outperform over time. So while a penny of earnings here or there is not going to dominate the discussion around Devon Energy (NYSE:DVN) or Ultra Petroleum (NYSE:UPL), investors would do well to dig in and appreciate what distinguishes the best operators. 


http://stocks.investopedia.com/stock-analysis/2010/Earnings-From-A-Couple-of-Gas-Giants-DVN-UPL-APA-SWN-CHK0511.aspx

Transocean Far From Sunk

There is no need to minimize just how serious the Deepwater Horizon oil spill in the Gulf of Mexico could ultimately be. Workers died in the accident, billions of dollars in damage are likely, a valuable rig is now scrap metal, and opponents of offshore drilling will make hay from this accident for years to come. 

All of that being said, the decline in market value of offshore driller Transocean (NYSE: RIG) seems to be exaggerating the ultimate impact to the company and its future prospects. With earnings out last week and a growing sense of the worst-case scenarios, the nervous hands may be all but gone from this story.  

http://stocks.investopedia.com/stock-analysis/2010/Transocean-Far-From-Sunk-RIG-BP-CAM-SII-PBR-FTI-CGV-HAL-APA-XOM0511.aspx

Monday, May 10, 2010

FDA Makes InterMune Sick (ITMN, GSK, AZN, GILD, VRTX, ACHN, VRUS)



I originally wrote this piece right after InterMune announced its FDA setback, but there was a bit of a logjam in the editing process. In any case, there are still some valuable points here. 

Failure is an inherent risk in the boom-and-bust world of biotech, and InterMune (Nasdaq: ITMN) shareholders saw that risk play out on Wednesday morning. The FDA effectively rejected the company's application for marketing approval of Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis. 

Clearly the damage has already been done, but what InterMune investors must decide now is whether there is enough promise in the drug and the company to hang on in the hopes of a rebound. 

For the rest of the article, please click on the following link:
http://stocks.investopedia.com/stock-analysis/2010/FDA-Makes-InterMune-Sick-ITMN-GSK-AZN-GILD-VRTX-ACHN-VRUS0510.aspx

Friday, May 7, 2010

Greece: The Worst-Case Scenario

This (http://financialedge.investopedia.com/financial-edge/0510/Greece-The-Worst-Case-Scenario.aspx) went up yesterday afternoon, so I apologize for the late posting.

While there has been a great deal of attention paid over the last few months to the nascent recovery in the United States, the ongoing Greek sovereign debt crisis in Europe is a reminder that there are often long-tail effects to recessions and global economic shake-ups. 


How Did This Happen?What has happened is the result of a long series of bad decisions. The establishment of the euro effectively gave Greece access to a huge amount of relatively cheap debt, but Greek officials did not put the proceeds of this debt to good use. Since the euro came into existence, Greece's ratio of debt to GDP has stayed above 100% and the country ran persistent deficits in excess of 10% of GDP. Ultimately, when investors (and, belatedly, the ratings agencies) realized that the emperor had no clothes, rates on Greek debt began to creep up, and matters culminated in the S&P downgrade of Greek debt to "junk" status on April 27 of 2010.

For the rest, please click on through to:  http://financialedge.investopedia.com/financial-edge/0510/Greece-The-Worst-Case-Scenario.aspx

Thursday, May 6, 2010

Ouch! Nasty Whiplash

This is why I try to keep the TV-watching to a minimum during the workday. In maybe 20 minutes I've seen the market plummet from down 5% to down more than 9% to now down about 4% (and climbing).

This is a pretty good microcosm of why I got out of the business ... there's way too much doing and not nearly enough thinking. Now, I'll grant that the decline may have really accelerated because of the impact of program trading, but that's not all of it. Institutions will program in stops at, say, the 200-day moving average, and then you can get just a cascade of selling as all of those stops trigger and force sell orders.


But it's pretty clear that people are really jittery and easily spooked these days. It seems like traders watched the news, saw unrest in Athens, and decided to de-risk their holdings. As the markets dropped, rates moved fast (as did gold, though to a lesser extent) and things snowballed.

At this point, nobody wants any risk. It wouldn't shock me to see the market close weak (despite this intraday rebound), as I doubt nervous traders want to hold equities overnight. So when you have panicky people, you get panic selling.

Is this is a great buying opportunity? I don't think so.

You and I can't buy nimbly enough to really profit off of these large intraday moves. So while I see a lot of volatility and nervousness in the near term, I think it is very difficult to play that effectively. The best advice is probably old advice - buy good stocks at prices that give you a wide margin of safety. And, to be very frank, it may just be time to step away for a bit and let things settle down.

This is *not* the end of the recovery, *not* the end of the euro, and *not* the end of the world. But what good does that do you when hyperactive traders all scream "sell" at once?

Australia Proves Taxing To Miners

The latest article on Investopedia:
http://stocks.investopedia.com/stock-analysis/2010/Australia-Proves-Taxing-To-Miners-RTP-BTU-FSUMY-ABX-NEM-FCX-VALE0506.aspx

I'll be very curious to see how debate in Australia shapes this issue. Mining is a major source of income for the country and Australia derives huge benefit from being a modern and mineral-rich nation relatively close to China. Here's hoping they don't strangle the golden goose. 

One of the biggest risks that go along with investing in mining stocks is the risk that sovereign governments will change the rules midstream. More than a few mining projects in Africa and South America have been canceled or curtailed by governments suddenly changing the rules, typically by tearing up contracts demanding a larger slice of the pie. Historically, Australia has been seen as a very mining-friendly country, but a recent proposal to change tax rules in that country has sent some major ripples through the sector.


The TaxAs part of a comprehensive tax policy review, the Australian government has proposed a new "resource super profit tax" of 40% that would be levied on companies with on-shore mining assets in Australia. In short, this tax would increase the effective corporate tax rate for mining in Australia to about 57%. Another way to look at it is that basically makes the government of Australia a 40% partner in all resource projects starting in the summer of 2012. 
 
For the full article, please go to: http://stocks.investopedia.com/stock-analysis/2010/Australia-Proves-Taxing-To-Miners-RTP-BTU-FSUMY-ABX-NEM-FCX-VALE0506.aspx